denv-2

NITD008 (7-Deaza-2'-C-acetylene-adenosine) is a potent and selective adenosine nucleoside inhibitor.NITD008 is an adenosine nucleoside analog with broad-spectrum antiviral activity that inhibits dengue, animal cupripoxvirus, and Zika virus.

DENV-IN-2 is a highly effective inhibitor of dengue viral replication with a potency indicated by an EC 50 of 0.016 nM. It exhibits significant activity against all four serotypes of the Dengue virus, with EC 50 values ranging from 0.013 to 0.029 nM.

Denv-in-5 is an effective and selective dengue virus (DENV) inhibitor with EC50 values of 1.47, 9.23, 7.08, 8.91 μM for denV-I-IV and 0.1512 μM for HIV-1IIIB.

ML-SA1 (Mucolipin synthetic agonist 1) is a selective TRPML agonist, inhibits Dengue virus 2 (DENV2) and Zika virus (ZIKV) by promoting lysosomal acidification and protease activity. The IC50 value of ML-SA1 against DENV2 RNA and ZIKV RNA is 8.3 μM and 52.99 μM, respectively[1].

A181 (AI-181) is a DENV-2 inhibitor, suitable for use in dengue fever research.

Panduratin A is a natural chalcone derivative with inhibitory activity against MMP-9 in human oral epidermoid carcinoma KB cells; inhibitory activity against the NS3 protease of DENV-2 (Ki=25 μM); significant cytotoxicity against human androgen-independent prostate cancer cells PC-3 and DU-145; and also able to activate the LKB1-AMPK- PPARα δ signaling pathway and enhance the oxidative capacity of myocyte mitochondria.

LL-37 is a cationic and α-helical antimicrobial peptide expressed in human bone marrow, testis, granulocytes, and gingival epithelium and is upregulated in psoriatic lesions. It inhibits growth of Gram-positive E. coli D21 and Gram-negative B. megatarium in a concentration-dependent manner and LL-37 expression is induced in A549 epithelial cells, alveolar macrophages, neutrophils, and monocyte-derived macrophages following M. tuberculosis infection. LL-37 binds sheep erythrocytes coated with S. minnesota Re-LPS and induces agglutination with a minimal agglutinating concentration (MAC) of 12.1 μg/ml. It is a chemoattractant for, and can induce calcium mobilization in, human monocytes, neutrophils, and T cells that naturally express formyl peptide receptor-like 1 (FPRL1) and FPRL1-transfected HEK293 cells. LL-37 (10-15 μM) pretreatment of dengue virus type 2 (DENV-2) reduces its infectivity as well as levels of viral genomic RNA and NS1 antigen. In vivo, LL-37 inhibits cecal ligation and puncture-induced caspase-1 activation and pyroptosis of peritoneal macrophages, reduces levels of the inflammatory cytokines IL-1β, IL-6, and TNF-α, and improves survival in polybacterial septic mice.

GAK inhibitor 2 (Compound 14g) is a highly potent inhibitor of cyclin G-associated kinase (GAK) with an IC50 of 0.024 μM and exhibits remarkable antiviral activity against dengue virus (DENV) with an EC50 of 1.049 μM [1].

NS2B NS3-IN-2 is a potent, covalent inhibitor of dengue virus (DENV) NS2B NS3 with an IC50 of 6.0 nM and a Ki of 0.66 μM. It significantly increases cell viability and exhibits no cytotoxicity.

RK-0404678 is a novel inhibitor of dengue virus NS5 RNA-dependent RNA polymerase (RdRp), inhibiting the DENV type 2 (DENV2) RdRp activities.

DENV-IN-10 is a potent tetravalent inhibitor of the dengue virus, with half-maximal effective concentrations (EC50s) of 1.36, 0.87, 0.94, and 0.95 μM against DENV-1, DENV-2, DENV-3, and DENV-4 serotypes, respectively. Functioning as a post-entry replication inhibitor, DENV-IN-10 demonstrates specificity for primate-origin cells [1].

Antiviral agent 36 (compound 27), a potent inhibitor of both dengue (DENV) and Zika (ZIKV) viruses, demonstrates replication inhibition with EC50 values of 100 nM for ZIKV-FLR, 90 nM for ZIKV-HN16, 210 nM for DENV-2, and 120 nM for DENV-3 [1].

DENV-IN-12 (Compound 6), a derivative of N-methylcytisine thio, effectively inhibits both DENV-1 and DENV-2. It demonstrates strong antiviral activity against DENV-2, with EC50 values between 0.002 and 0.005 μM across various cell lines [1].

NITD-2 is a dengue virus (DENV) polymerase inhibitor, inhibits the DENV RdRp-mediated RNA elongation. NITD-2 penetrates cell membrane poorly. Dengue virus (DENV) is the most prevalent mosquito- borne viral pathogen in humans. Neither vaccine nor antiviral therapy is currently available for DENV.

Caffeoylcalleryanin demonstrated potent inhibitory activity against 15-lipoxygenase (15-LOX), with an IC50 value of 1.59 μM. Furthermore, ethanol extract from A. pulchra leaves (EEAPL) was found to contain compounds exhibiting antiviral properties, particularly effective against Dengue virus type 2 (DENV-2). Among these compounds, Caffeoylcalleryanin emerged as the most potent anti-DENV-2 agent, achieving a selectivity index (SI) of 20.0.

Antiviral agent 51 (compound a), a potent fucoidan-based antiviral, interacts with DENV-2 RNA Dependant RNA polymerase (RdRp) [1].